Small cell lung cancer extensive stage
RecruitingStudy Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer
- Disease:Small cell lung cancer extensive stage
- Substances:TopotecanSacituzumab Govitecan
Hungary- Participants:18–64 years · 65+ years
- Substances:Topotecan
- Sponsor:Gilead Sciences Inc.














